Vanguard Group Inc. boosted its holdings in shares of STAAR Surgical (NASDAQ:STAA - Free Report) by 5.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,855,570 shares of the medical instruments supplier's stock after buying an additional 319,441 shares during the quarter. Vanguard Group Inc. owned approximately 11.88% of STAAR Surgical worth $142,232,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Quarry LP purchased a new position in shares of STAAR Surgical during the 3rd quarter worth $50,000. KLP Kapitalforvaltning AS purchased a new position in STAAR Surgical during the fourth quarter valued at $180,000. FMR LLC grew its holdings in STAAR Surgical by 79.3% during the third quarter. FMR LLC now owns 7,092 shares of the medical instruments supplier's stock valued at $263,000 after purchasing an additional 3,136 shares during the period. Quantbot Technologies LP purchased a new stake in STAAR Surgical in the fourth quarter worth about $278,000. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of STAAR Surgical in the fourth quarter worth about $292,000. 96.70% of the stock is owned by hedge funds and other institutional investors.
STAAR Surgical Price Performance
Shares of STAA stock traded up $1.22 during trading hours on Friday, hitting $16.79. The stock had a trading volume of 1,170,915 shares, compared to its average volume of 790,156. The stock has a market capitalization of $828.17 million, a price-to-earnings ratio of -40.95 and a beta of 0.75. STAAR Surgical has a one year low of $13.50 and a one year high of $51.34. The stock's 50-day moving average price is $17.66 and its two-hundred day moving average price is $24.00.
Wall Street Analysts Forecast Growth
A number of brokerages recently issued reports on STAA. Needham & Company LLC reiterated a "hold" rating on shares of STAAR Surgical in a research note on Thursday, February 27th. BTIG Research cut shares of STAAR Surgical from a "buy" rating to a "neutral" rating in a research note on Wednesday, February 12th. Piper Sandler decreased their price objective on shares of STAAR Surgical from $40.00 to $16.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 12th. Mizuho lowered STAAR Surgical from an "outperform" rating to a "neutral" rating and cut their price target for the stock from $45.00 to $17.00 in a research note on Wednesday, February 12th. Finally, William Blair cut STAAR Surgical from an "outperform" rating to a "market perform" rating in a report on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $25.29.
View Our Latest Analysis on STAA
Insider Buying and Selling at STAAR Surgical
In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. acquired 8,200 shares of the stock in a transaction on Wednesday, April 9th. The stock was acquired at an average price of $15.08 per share, for a total transaction of $123,656.00. Following the completion of the transaction, the insider now directly owns 13,518,591 shares of the company's stock, valued at $203,860,352.28. This trade represents a 0.06 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders bought 1,771,957 shares of company stock worth $29,038,281 in the last quarter. 1.00% of the stock is owned by corporate insiders.
About STAAR Surgical
(
Free Report)
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
See Also
Before you consider STAAR Surgical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STAAR Surgical wasn't on the list.
While STAAR Surgical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
